GlassScriptPhysician profile
Michael Alan Crim
NPI 1982609699
$5,117.25
in general payments reported to CMS, 2019-2025
42 companies · $807 in 2025
The $807 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $207 · 2021: $630 · 2022: $970 · 2023: $1,114 · 2024: $1,144 · 2025: $807.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $814.35 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $567.47 | 2022-2025 | Freestyle Libre 3 |
| Abbvie INC. | $549.62 | 2020-2025 | Vraylar, Ubrelvy |
| Amgen INC. | $431.32 | 2019-2025 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $426.27 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $391.29 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $255.43 | 2019-2025 | |
| Amarin Pharma, INC. | $247.25 | 2019-2022 | |
| Glaxosmithkline, LLC. | $160.75 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Janssen Pharmaceuticals, INC | $160.45 | 2019-2024 | Xarelto, Spravato |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.79 | 2022-2024 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $77.08 | 2022-2023 | Verquvo, Steglatro, Belsomra |
| Sumitomo Pharma America, INC. | $71.42 | 2023-2025 | Gemtesa |
| Sanofi-Aventis U.S. LLC | $70.90 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $62.87 | 2021-2025 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Crim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.